Clinical trials: Super-Refractory Status Epilepticus
Super-refractory Status Epilepticus
KD Treatment for Super-refractory Status Epilepticus
The purpose of the study is to investigate to evaluate the efficacy and safety of ketogenic diet (KD) as an adjunctive therapy in patients with Super Refractory Status Epilepticus (SRSE) in the intensive care unit (ICU).
- Trial name
- KD (NCT07496749)
- Testing
- the ketogenic diet, Standard Medical Therapy
- Where
- 14 sites in China
- Volunteers
- 84 people
- Sponsor
- Xuanwu Hospital, Beijing
Super-refractory Status Epilepticus
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
- Trial name
- SRSE (NCT02052739)
- Testing
- SAGE-547
- Where
- 17 sites in United States
- Volunteers
- 25 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Super-Refractory Status Epilepticus
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
This is an open-label, expanded access protocol, designed to offer treatment with SAGE-547 to subjects in SRSE, and to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to these…
- Trial name
- NCT02433314
- Testing
- SAGE-547
- Sponsor
- Supernus Pharmaceuticals, Inc.
Super-Refractory Status Epilepticus
A Study With SAGE-547 for Super-Refractory Status Epilepticus
This is a randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to subjects in Super-Refractory Status Epilepticus (SRSE).
- Trial name
- NCT02477618
- Testing
- SAGE-547
- Where
- 171 sites in United States, Austria and 14 more
- Volunteers
- 132 people
- Sponsor
- Supernus Pharmaceuticals, Inc.